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Life in the fast lane: Developing and commercializing KEYTRUDA®, a novel breakthrough therapy
designation oncology therapy, in three years from first patient dosed to US approval.
Gargi Maheshwari*, Athena Nagi, Ronald Smulders, Fergal O’Donovan, Kimberly May, Tamas Blandl,
Marc Bastiaansen
*Executive Director, Biologics Process Development & Commercialization, Merck & Co.
In order to accelerate the availability of novel potentially life-saving therapies, the FDA has developed
multiple programs, including recently assigning breakthrough therapy designation to promising
candidates in development. At the time of breakthrough therapy designation, Merck had only
manufactured supplies at a small clinical scale facility. In order to meet forecasts for projected
commercial and clinical demand and to ensure uninterrupted supply for Keytruda®, a novel monoclonal
antibody against PD-1, Merck commercialized two drug substance facilities in parallel. Through multiple
interactions with the FDA, both facilities were licensed, one that was the initial clinical supply site, and, a
second larger CMO site. The licensure of these two sites was based on a strong process and analytical
comparability package. In this case study, the author will present the challenges and opportunities
encountered via this multi-site strategy to supplying KEYTRUDA®. The focus will be on approaches taken
towards late stage commercialization activities including process characterization and process
performance qualification. The author will also highlight post approval activities that follow as a
consequence of an accelerated CMC development timeline.

